Impaired Glycosylation of Vascular Endothelial Growth Factor Receptor 2 in Tumor Angiogenesis
Impaired Glycosylation of Vascular Endothelial Growth Factor Receptor 2 in Tumor Angiogenesis
批准号:
9215653
负责人:
Kevin Brown Chandler
金额:
$5.92万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-01 至 2018-03-31
关键词:
AffectAngiogenic SwitchBAY 54-9085Binding ProteinsBlood VesselsCell membraneCell surfaceClathrinDevelopmentDrug resistanceEndocytosisEndosomesEndothelial CellsExposure toGlycopeptidesGoalsGolgi ApparatusGrowthHypoxiaImaging TechniquesImmunoprecipitationImpairmentKDR geneKnowledgeLeadLigandsMalignant NeoplasmsMass Spectrum AnalysisMediatingMembraneMolecular BiologyNeoplasm MetastasisOrganellesPathologicPathologic NeovascularizationPatternPhosphorylationPlayPolysaccharidesPopulationProcessProtein GlycosylationProteinsProteomicsReceptor ActivationReceptor Protein-Tyrosine KinasesReceptor SignalingRecyclingResidenciesResistanceResistance developmentRoleSignal TransductionSubcellular FractionsTumor AngiogenesisTumor Cell LineUV Radiation ExposureVascular Endothelial Growth FactorsVascularizationWestern BlottingWorkangiogenesisantiangiogenesis therapybevacizumabcancer therapycrosslinkextracellularglycoproteomicsglycosylationinhibitor/antagonistlink proteinmolecular imagingmulticatalytic endopeptidase complexnovelproteostasispublic health relevancereceptorscreeningsugartraffickingtumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Angiogenesis (the development of new blood vessels from established vasculature) is essential for tumor growth and metastasis. Vascular endothelial growth factor receptor 2 (VEGFR-2) is a receptor tyrosine kinase (RTK) involved in angiogenic signaling in normal and pathological conditions. Tumors frequently express high levels of hypoxia-induced VEGF ligands that target VEGFR-2 to support tumor vascularization and growth. While VEGFR-2 inhibitors including bevacizumab, sorafenib and sunitinib are used for cancer treatment, the development of resistance to these agents poses an obstacle to effective management of cancer. Recently, impaired trafficking and ligand-independent VEGFR-2 activation and signaling in the Golgi have been demonstrated. Intriguingly, disruption of N-glycosylation affects VEGFR-2 trafficking and may play a role in this process. However, the impact of VEGFR-2 glycosylation on trafficking and receptor activation is largely unexplored. We hypothesize that altered protein glycosylation in pathological circumstances contributes to the sustained localization of VEGFR-2 to the Golgi apparatus by affecting trafficking of VEGFR-2 and leads to ligand-independent activation and signaling from the Golgi. Therefore, we propose to study the impact of VEGFR-2 glycosylation on VEGFR-2 trafficking and activation. We plan to explore this hypothesis by (A) establishing the glycosylation status of membrane and subcellular fractions of VEGFR-2 and examining their impact on receptor activation, (B) screening for glycosylation-dependent VEGFR-2 protein interactions in cell membrane and Golgi fractions, and (C) investigating the role of VEGFR-2 glycosylation in protein recycling, turnover and degradation. A major goal of this proposal is to explore the role of glycosylation in VEGFR-2 trafficking, signaling and aberrant tumor angiogenesis. I will analyze VEGFR-2 glycopeptides and released N-glycans and screen for VEGFR-2 glycosylation-dependent protein interactions using UV-activated crosslinking sugars via mass spectrometry. Results from this study will illuminate the role of glycosylation in VEGFR-2 trafficking and signaling, including: characterization of differences in glycosylation between Golgi and extracellular fractions, assessment of changes in receptor activation and signaling associated with changes in glycosylation, identification of glycosylation-specific VEGFR-2 interacting partners that modulate VEGFR-2 trafficking, and determination of the impact of receptor glycosylation on protein recycling and degradation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Impaired Glycosylation of Vascular Endothelial Growth Factor Receptor 2 in Tumor Angiogenesis
-
批准号:8908429
-
项目类别:
-
资助金额:$5.24万
-
财政年份:2015
-
负责人:Kevin Brown Chandler
-
依托单位:
Impaired Glycosylation of Vascular Endothelial Growth Factor Receptor 2 in Tumor Angiogenesis
-
批准号:9404509
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2015
-
负责人:Kevin Brown Chandler
-
依托单位:
国内基金
海外基金
线粒体应激促进肿瘤第一条新生血管(Angiogenic Switch)生成的作用机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:罗慧
-
依托单位: